Federico Cayol, Gabriela Gatica, Pablo Companys, Carolina Passarella, Rodrigo Sanchez, Ernesto Korbenfeld, Jose Zarba, Omar Carranza, Ruben Kowalyszyn, Gonzalo Taetti, Martín Richardet, Ezequiel Espamer, Mauricio Fernandez Lazaro, Laura Pelagatti, Nicolas Mainardi, Matías Cortes, José Peñaloza, Hernan Cutuli, María Pía Dominguez, Harold Somerville, Florencia Sarru, Juan Pablo Sade, Augusto Ferreyra Camacho, Emiliano Menna, Ivan Macharashvili, Rosalía Hinojosa Altamirano, Andrea Marchioni, Federico Losco, Pamela López, Tomas Soule, Mariano Aymar, Ignacio Jerez, Juan Ignacio Hernández Morán, María Natalia Gandur Quiroga, Martín Angel
{"title":"阿根廷转移性肾透明细胞癌的治疗趋势。","authors":"Federico Cayol, Gabriela Gatica, Pablo Companys, Carolina Passarella, Rodrigo Sanchez, Ernesto Korbenfeld, Jose Zarba, Omar Carranza, Ruben Kowalyszyn, Gonzalo Taetti, Martín Richardet, Ezequiel Espamer, Mauricio Fernandez Lazaro, Laura Pelagatti, Nicolas Mainardi, Matías Cortes, José Peñaloza, Hernan Cutuli, María Pía Dominguez, Harold Somerville, Florencia Sarru, Juan Pablo Sade, Augusto Ferreyra Camacho, Emiliano Menna, Ivan Macharashvili, Rosalía Hinojosa Altamirano, Andrea Marchioni, Federico Losco, Pamela López, Tomas Soule, Mariano Aymar, Ignacio Jerez, Juan Ignacio Hernández Morán, María Natalia Gandur Quiroga, Martín Angel","doi":"10.1200/GO-24-00342","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina.</p><p><strong>Methods: </strong>A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time.</p><p><strong>Results: </strong>Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate.</p><p><strong>Conclusion: </strong>The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400342"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina.\",\"authors\":\"Federico Cayol, Gabriela Gatica, Pablo Companys, Carolina Passarella, Rodrigo Sanchez, Ernesto Korbenfeld, Jose Zarba, Omar Carranza, Ruben Kowalyszyn, Gonzalo Taetti, Martín Richardet, Ezequiel Espamer, Mauricio Fernandez Lazaro, Laura Pelagatti, Nicolas Mainardi, Matías Cortes, José Peñaloza, Hernan Cutuli, María Pía Dominguez, Harold Somerville, Florencia Sarru, Juan Pablo Sade, Augusto Ferreyra Camacho, Emiliano Menna, Ivan Macharashvili, Rosalía Hinojosa Altamirano, Andrea Marchioni, Federico Losco, Pamela López, Tomas Soule, Mariano Aymar, Ignacio Jerez, Juan Ignacio Hernández Morán, María Natalia Gandur Quiroga, Martín Angel\",\"doi\":\"10.1200/GO-24-00342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina.</p><p><strong>Methods: </strong>A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time.</p><p><strong>Results: </strong>Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate.</p><p><strong>Conclusion: </strong>The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.</p>\",\"PeriodicalId\":14806,\"journal\":{\"name\":\"JCO Global Oncology\",\"volume\":\"11 \",\"pages\":\"e2400342\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO Global Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/GO-24-00342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina.
Purpose: Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends for patients with metastatic renal cell carcinoma (mRCC) in Argentina.
Methods: A retrospective study was conducted involving 689 patients with mRCC treated in Argentina between 2015 and 2022. The study analyzed treatment patterns and outcomes over time.
Results: Access to combination treatments for mRCC in Argentina has increased significantly, with 87% of patients receiving such therapies during the 2021-2022 period. The real-world data demonstrated that combination treatments in this Latin American population resulted in prolonged progression-free survival and improved overall response rate.
Conclusion: The results underscore the importance of ensuring access to combination therapies for patients with mRCC in Latin America. These findings should inform public health policies aimed at guaranteeing access to effective combination therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
